StreetAlpha.app
Home › Stocks › RGNX

REGENXBIO Inc. (RGNX)

Healthcare
$7.24
▼ −1.09%
LAST CLOSE · NOV 17

REGENXBIO develops gene therapies that use AAV vectors to deliver working genes into cells to treat disease. It last closed at $7.24 on Nov 17, down 1.09% on the day. The average 12-month price target from 3 analysts is $24.00 (+231.5% from the last close), with a high of $29.00 and a low of $21.00. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell).

AI Auto Pilots
Is RGNX in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$153.9M
−4.6% vs a year ago
Net income
−$175.2M
−113.9% margin
EPS (diluted)
−$3.20
Free cash flow
−$154.8M
−100.6% margin
Valuation
Market cap
$478.7M
66.1M shares
P/E
–
No P/E while losing money
Price to sales
3.1
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$95.8M
At Sep 30
Shareholder equity
$148.0M
Shares outstanding
66.1M
At Oct 30
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $470.3M$470.3MFY2021FY2022: $112.7M$112.7MFY2022FY2023: $90.2M$90.2MFY2023FY2024: $83.3M$83.3MFY2024FY2025: $170.4M$170.4MFY2025

From RGNX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Last report
Nov 5
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 3 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
3firms
3 Buy0 Hold0 Sell
Each firm's latest rating on RGNX in the past 90 days
Average 12-month target
$24.00
▲ 231.5% upside

Based on 3 analysts who set a price target on RGNX in the past 90 days. The average target is $24.00, with a high of $29.00 and a low of $21.00, compared with the last close of $7.24.

Low $21.00Avg $24.00High $29.00
Blue marker: last close $7.24
Highest target$29.00
Average target$24.00
Lowest target$21.00
Latest rating changes
MizuhoInitiated
Oct 5Buy$22
HC Wainwright & Co.Target lowered
Aug 25Buy$23 → $21
BairdTarget lowered
Aug 25Buy$32 → $29
HC Wainwright & Co.Target lowered
Aug 10Buy$26 → $23
HC Wainwright & Co.Reiterated
Jun 24Buy$26
DateFirmActionRatingPrice target
Oct 5MizuhoInitiatedBuy$22
Aug 25HC Wainwright & Co.Target loweredBuy$23 → $21
Aug 25BairdTarget loweredBuy$32 → $29
Aug 10HC Wainwright & Co.Target loweredBuy$26 → $23
Jun 24HC Wainwright & Co.ReiteratedBuy$26
Loading…

Technical Analysis

RGNX · as of the Nov 17 close · updated after every close
Moving sideways

The stock is 2% below its 20 day and 5% below its 50 day average. It is 22% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 46). The nearest support is the swing low (Oct 7) at $7.20, and the nearest resistance the swing high (Jun 1) at $7.32.

Short trendNeutral
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityNormal, 8.1%/day
Key levels
$16.1952 week high+123.6%
$9.26100 day average+27.9%
$8.84200 day average+22.1%
$7.5950 day average+4.8%
$7.54Pivot R1+4.1%
$7.4020 day average+2.2%
$7.32Swing high (Jun 1)+1.1%
$7.24Last close
$7.20Swing low (Oct 7)−0.6%
$7.19Pivot−0.7%
$6.89Pivot S1−4.8%
$5.4652 week low−24.6%
Indicators
RSI (14)45.82Middle of its rangeNeutral
MACD0.01Above its signal lineBullish
Stochastic34.2Middle of its rangeNeutral
ADX (14)13.0No clear trend
Williams %R-80.4Oversold below −80, overbought above −20Oversold
CCI (20)-40.7Oversold below −100, overbought above 100Neutral
Rate of change−5.1%Change over 10 sessionsBearish
ATR (14)$0.58Typical daily range, 8.1% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for RGNX

What happened before

See how RGNX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow RGNX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How RGNX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2015.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in RGNX in the last 90 days.

Loading…

See today’s whale options flow across the market →

RGNX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲110 buying vs 64 selling
  • ▲Held by funds +18.0 pts
  • ▲Funds holding +8
  • ▲Superinvestors: 3 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding174166+4.8%
In funds' top 1012−50.0%
Held by funds82.1%64.1%+18.0 pts
New / increased33 / 7725 / 62+26.4%
Reduced / sold out41 / 2352 / 35−26.4%
Put/call ratio1.000.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See RGNX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether RGNX is in one of them and how their past RGNX trades turned out.

RGNX in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered RGNX in an article yet. Here's the latest on the wider market.

RGNX Congress Trades

All congress trades →
Trades, 12 months
0
Buys
0
Sells
0
People
0
Last filed Nov 14
Who traded RGNX · since 2019
Latest 2 filings
$1K – $15KTraded Nov 8, 2019Filed Nov 14, 2019
$1K – $15KTraded Oct 22, 2019Filed Nov 14, 2019
PersonTypeAmountTradedFiledDelay
Peter WelchD · VTSell$1K – $15KNov 8, 2019Nov 14, 20196 d
Peter WelchD · VTBuy$1K – $15KOct 22, 2019Nov 14, 201923 d

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About REGENXBIO

REGENXBIO is a biotechnology company based in Rockville, Maryland, that develops gene therapies. Its treatments use modified viruses called AAV vectors, which are designed to deliver working genes into cells. The company's own pipeline targets eye, muscle and nervous system diseases. It also licenses its vector platform to drugmakers such as AbbVie and Novartis, which develop treatments for their own patients.

Headquarters
Rockville, MD